NCT02581631/ CheckMate 436 (Clinical Trial / Brentuximab Vedotin / Adcentris®)

Study Title
A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) NCT02581631

Trial Description
This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.

This trial is sponsored by Bristol-Myers Squibb® in collaboration with Seattle Genetics®

Study Data

  • Condition: Non-Hodgkin’s Disease
  • Interventions:
  • Phase: I & II
  • Enrollment: 96
  • Start: December 2015
  • Estimated Completion: December 2018
  • Last verified: December 2016
  • Last Updated: December 2016

Study Schematic

NCT02581631/ CheckMate 436 (Clinical Trial / Brentuximab Vedotin / Adcentris®)

Click here to Return to Drug map


Last Editorial review: December 13, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.